Low-Dose, Long-Term, Intermittent Interferon-alpha-2b Therapy after Radical Treatment by Radiofrequency Ablation Delays Clinical Recurrence in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma
- 1 March 2005
- journal article
- clinical trial
- Published by S. Karger AG in Intervirology
- Vol. 48 (1), 64-70
- https://doi.org/10.1159/000082097
Abstract
Objective: To assess whether or not interferon (IFN) therapy prevents recurrence, and eventually improves the prognosis of patients with hepatocellular carcinoma (HCC) after completion of radical radiofrequency ablation (RFA) therapy. Methods: Included as the IFN group in this study were 24 patients in total, who received radical RFA therapy first, followed by medication with IFN-α2b at such a low dose of 3 MIU × 2/week for as long as possible. On the other hand, the control group comprised 33 patients in total, who received radical RFA therapy without subsequent treatment with IFN. The control group was matched to the IFN group in age, platelet counts and size of nodules. Results: Of the 24 patients treated with IFN, only one patient showed sustained virologic response. The median tumor-free period until the first recurrence after radical RFA therapy was 3.4 years in the IFN group and 1.4 years in the control group (p = 0.02). During the first 3 years after commencement of IFN administration, the cumulative recurrence rate in the IFN group was found to be lower than in the control group (p = 0.01); however, with the lapse of time over 3 years, the recurrence rate in the IFN group increased. There was no difference in the cumulative survival rates between the IFN group and the control group (p = 0.25). Conclusion: Subsequently after radical RFA therapy, long-term, low-dose, intermittent IFN therapy successfully delayed clinical recurrence of HCC.Keywords
This publication has 25 references indexed in Scilit:
- Local ablation therapy for hepatocellular carcinoma: current status and future perspectivesThe Esophagus, 2004
- Prospective randomized controlled study of interferon‐alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumorsCancer, 2004
- Significance of multicentric cancer recurrence after potentially curative ablation of hepatocellular carcinoma: a longterm cohort study of 892 patients with viral cirrhosisThe Esophagus, 2003
- Mechanism of Interferon Alpha on Inhibition of Metastasis and Angiogenesis of Hepatocellular Carcinoma After Curative Resection in Nude MiceJournal of Gastrointestinal Surgery, 2003
- Relationship between response to previous interferon therapy and postoperative recurrence of hepatitis C virus-related hepatocellular carcinomaHepatology Research, 2002
- Influence of Previous Interferon Therapy on Recurrence after Resection of Hepatitis C Virus‐related Hepatocellular CarcinomaJapanese Journal of Cancer Research, 2001
- Molecular mechanisms underlying interferon-α-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteinsOncogene, 1999
- Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysisHepatology, 1999
- Treatment of Chronic Hepatitis C with Recombinant Interferon AlfaNew England Journal of Medicine, 1989